(Total Views: 534)
Posted On: 10/30/2024 7:58:34 PM
Post# of 148845
Dr. Palmer extra bio info:
for all liver diseases including MASH and PSC, all aspects of liver disease drug development from pre-IND to NDA and launch, hepatic impairment studies, regulatory interactions including IND, NDA, and responding to regulatory feedback from the Agencies, liver adverse event signal evaluation during clinical trials, (drug-induced liver injury, formation of and chairing scientific and medical advisory boards, data-safety monitoring committees and Hepatology safety adjudication committees.
https://rectifypharma.com/
for all liver diseases including MASH and PSC, all aspects of liver disease drug development from pre-IND to NDA and launch, hepatic impairment studies, regulatory interactions including IND, NDA, and responding to regulatory feedback from the Agencies, liver adverse event signal evaluation during clinical trials, (drug-induced liver injury, formation of and chairing scientific and medical advisory boards, data-safety monitoring committees and Hepatology safety adjudication committees.
https://rectifypharma.com/
(2)
(0)Scroll down for more posts ▼
